Почетна › Кронова болест › Охајо
Клинички испитувања за Кронова болест во Охајо
30 студии за Кронова болест бараат учесници на локации во Охајо.
Градови во Охајо
Официјален текст на студијата (англиски)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 2.10.2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT07697456Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 75 · Сите полови · Ажурирано 1.10.2026 · NCT07852273A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health Research - Cincinnati, Cincinnati
- DSI Research Northridge LLC, Dayton
- Gastro Health Research - Liberty Township, Liberty Township
- и уште 3
Се регрутираФаза 4
Возраст од 18 до 80 · Сите полови · Ажурирано 30.9.2026 · NCT06581328Non-nutritive Sweeteners in Inflammatory Bowel Disease
- UH Minoff Health Center, Chagrin Falls
- University Hospitals Cleveland Medical Center, Cleveland
- UH Westlake Health Center, Westlake
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 70 · Сите полови · Ажурирано 25.9.2026 · NCT07769437Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Cincinnati /ID# 265589, Cincinnati
- The Ohio State University /ID# 265577, Columbus
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 25.9.2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07499232A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cincinnati Children's Hospital Medical Center, Cincinnati
Се регрутираФаза 3
Возраст 3 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06663332A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 25.9.2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
- University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
- Ohio Gastroenterology Group Inc.-8400006, Columbus
- и уште 5
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 23.9.2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
- Medical Associates Research Group-Site Number: 8400063, Columbus
- OSU Wexner Medical Center-Site Number: 8400077, Columbus
- и уште 1
Се регрутираФаза 3
Возраст од 16 до 80 · Сите полови · Ажурирано 23.9.2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Cleveland Clinic - Cleveland /ID# 256453, Cleveland
Се регрутираФаза 3
Возраст од 2 до 17 · Сите полови · Ажурирано 23.9.2026 · NCT05995353A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Cincinnati, Cincinnati
- Ohio Gastroenterology group, Inc., Columbus
- Great Lakes Gastroenterology Research, LLC, Mentor
- и уште 1
Се регрутираФаза 4
Возраст од 18 до 70 · Сите полови · Ажурирано 9.9.2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Great Lakes Gastroenterology Research, LLC, Mentor
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT07577843Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
- Cleveland Clinic, Cleveland
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 27.8.2026 · NCT07680283A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Childrens Medical Center, Dayton
Се регрутираФаза 3
Возраст од 2 до 17 · Сите полови · Ажурирано 24.8.2026 · NCT05509777Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Cincinnati, Cincinnati
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 5.8.2026 · NCT07237516Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- UH Cleveland Medical Center /ID# 262188, Cleveland
Се регрутираФаза 3
Возраст од 2 до 17 · Сите полови · Ажурирано 24.6.2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
Се регрутираФаза 3
Возраст од 2 до 17 · Сите полови · Ажурирано 22.6.2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cincinnati Children's Hospital Medical Center, Cincinnati
- UH/Rainbow Babies and Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
Се регрутираФаза 4
Возраст од 6 до 17 · Сите полови · Ажурирано 27.5.2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
Се регрутираФаза 3
Возраст 2 и постари · Сите полови · Ажурирано 7.5.2026 · NCT05442567Precise Infliximab Exposure and Pharmacodynamic Control
- Cincinnati Children's Hospital, Cincinnati
- Cleveland Clinic Children's Hospital, Cleveland
- Nationwide Children's Hospital, Columbus
Се регрутираФаза 2/3
Возраст од 6 до 22 · Сите полови · Ажурирано 5.5.2026 · NCT05660746A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- University Hospitals Cleveland Medical Center, Cleveland
Се регрутираФаза 3
Возраст од 2 до 17 · Сите полови · Ажурирано 5.5.2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- OSU Inflammatory Bowel Disease Center, Hilliard
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 27.4.2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cincinnati
- Mirador Therapeutics Selected Site, Liberty Township
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 12.3.2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Cleveland Clinic, Cleveland
Се регрутираФаза 1/2
Возраст од 18 до 65 · Сите полови · Ажурирано 10.12.2025 · NCT06721962Evaluation of the SMART IBD App in Pediatric IBD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Се регрутира
Возраст од 13 до 17 · Сите полови · Ажурирано 21.11.2025 · NCT07195123Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Cleveland Clinic Foundation, Cleveland
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 12.11.2025 · NCT06670638Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.